Journal of pain and symptom management · 2026
Real-World Experience With Initiating Buprenorphine in Opioid Tolerant Patients with Cancer Pain.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Idom Olivia, Winget Marshall, Toye Amanda, Hande Karen, Mazzara Stephanie, Jackson Heather, Mundy Lindsay, Smith Jody B, El-Sourady Maie, Martin Sara F, Agarwal Rajiv, Butler Taylor
Аннотация
CONTEXT: Full-opioid agonists are commonly used for cancer-related pain but include risks such as constipation and respiratory depression. Buprenorphine, a partial opioid agonist, may offer a safer alternative, though concerns regarding withdrawal symptoms and efficacy remain. This study evaluates the real-world success of initiating buprenorphine in opioid tolerant patients for cancer-related pain management.
OBJECTIVES: Assess the success rate of initiating buprenorphine products in opioid tolerant patients with cancer-related pain and chronic pain with a history of cancer and evaluate associated clinical outcomes including pain control, withdrawal symptoms, and buprenorphine discontinuation.
METHODS: This retrospective, single-center study included adult patients with active or historical malignancy who initiated transdermal or buccal buprenorphine between January 2023 and June 2024. The primary outcome was a successful initiation at 30 days, defined as continued buprenorphine use, absence of withdrawal symptoms, and stable or improved pain scores.
RESULTS: A total of 77 patients were screened with 48 meeting inclusion criteria. Successful initiations occurred in 34 patients (71%). For the entire cohort, mean pain scores decreased from 6.3 at baseline to 4.9 at day 30. Withdrawal symptoms were reported in 8% of patients. On day 30, 77% remained on buprenorphine, and two patients resumed full-opioid agonists. Most patients who continued buprenorphine (65%) remained on their initial dose.
CONCLUSION: Buprenorphine appears to be a safe and effective alternative for managing cancer-related pain, with minimal withdrawal symptoms and stable or improved pain control. These findings support broader use of buprenorphine products in cancer-related pain management, though further prospective studies are needed.
OBJECTIVES: Assess the success rate of initiating buprenorphine products in opioid tolerant patients with cancer-related pain and chronic pain with a history of cancer and evaluate associated clinical outcomes including pain control, withdrawal symptoms, and buprenorphine discontinuation.
METHODS: This retrospective, single-center study included adult patients with active or historical malignancy who initiated transdermal or buccal buprenorphine between January 2023 and June 2024. The primary outcome was a successful initiation at 30 days, defined as continued buprenorphine use, absence of withdrawal symptoms, and stable or improved pain scores.
RESULTS: A total of 77 patients were screened with 48 meeting inclusion criteria. Successful initiations occurred in 34 patients (71%). For the entire cohort, mean pain scores decreased from 6.3 at baseline to 4.9 at day 30. Withdrawal symptoms were reported in 8% of patients. On day 30, 77% remained on buprenorphine, and two patients resumed full-opioid agonists. Most patients who continued buprenorphine (65%) remained on their initial dose.
CONCLUSION: Buprenorphine appears to be a safe and effective alternative for managing cancer-related pain, with minimal withdrawal symptoms and stable or improved pain control. These findings support broader use of buprenorphine products in cancer-related pain management, though further prospective studies are needed.